

Please delete the paragraph at lines 21-26 on page 1 and insert the following paragraph in place thereof:

-- The present invention contemplates altering the chemokine receptor ligands so that the ligands may be targeted to the endoplasmic reticulum. These molecules are herein termed intrakines. By "intrakine" is meant any ligand that binds to a C-C chemokine receptor at the cell surface but has been modified to be targeted to the ER of the lymphocyte or other intracellular organelle, such ligands include but are not limited to RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$ , for binding to CCR5 and stromal cell derived factor-1 (SDF-1) for binding to CXR4. --

**In the Claims:**

Please cancel claims 35-37 without prejudice. Applicants reserve the right to pursue the subject matter of these claims in continuing and divisional applications.

Please amend claims 1-3, 8-12, 17-18, 23, 34 and 38-39 as set forth below. A marked-up copy of the amended claims showing the changes made is included herewith.

1. (Twice Amended) An expression vector which comprises an expression region, wherein the expression region comprises:

a promoter;  
an intracellular retention signal sequence encoding region; and a chemokine encoding region;

wherein said intracellular retention signal sequence and said chemokine encoding region are expressed from said promoter as a single intrakine transcript; and wherein said expression vector is administered to a lymphocyte, a monocyte, a macrophage or a stem cell; and further wherein said lymphocyte, monocyte, macrophage or stem cell is transduced *ex vivo* with said expression vector.

2. (Amended) The expression vector of claim 1, further comprising a coding region encoding a secreted chemokine.